Aprea Therapeutics Inc (APRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.91M
Last updated: Nov 17, 2026 at 4:17 PM ET
Aprea Therapeutics Inc (APRE) Statistics
Aprea Therapeutics (APRE) has a market cap of $5.91M. It kept -423878.66% of revenue as net income over the last 12 months. Its share count is up 742.33% from a year earlier.
Total Valuation
| Market Cap | $5.91M |
|---|---|
| Latest price (Nov 17, 2026) | $0.45 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 62.55% over 52 weeks and trades 26.23% below its 50-day average.
| Beta (1Y) | 0.68 |
|---|---|
| 52-Week Change | -62.55% |
| 1-Month Change | -14.88% |
| 3-Month Change | -32.47% |
| 6-Month Change | -43.36% |
| 5-Year Change | -99.51% |
| Total Return (1Y) | -62.55% |
| Total Return (3Y CAGR) | -50.64% |
| Total Return (5Y CAGR) | -64.92% |
| Max Drawdown (1Y) | -67.75% |
| Max Drawdown (3Y) | -95.20% |
| Sharpe Ratio (1Y) | -1.03 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $0.61 |
| 200-Day Average | $0.73 |
| 52-Week Range | $0.40 to $1.29 |
| RSI (14 Days) | 40.2 |
| Average Volume (20 Days) | 223.19K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.67x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.67x |
|---|---|
| Quick Ratio | 9.67x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -41.47% and return on assets is -36.44% over the last 12 months.
| Return on Equity (ROE) | -41.47% |
|---|---|
| Return on Assets (ROA) | -36.44% |
| Asset Turnover | 0.00x |
Scores
APRE has an Altman Z-Score of -9.00, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.00 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $3.34K over the last 12 months is down 99.32% from the 12 months before.
| Revenue | $3.34K |
|---|---|
| Revenue Growth (YoY) | -99.32% |
| Gross Profit | $3.34K |
| Operating Income | -$15.28M |
| Pretax Income | -$14.14M |
| Net Income | -$14.14M |
| Reported EPS (TTM) | -$0.70 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 87.89% of the $38.81M in total assets.
| Cash and Equivalents | $37.85M |
|---|---|
| Total Debt | $0 |
| Net Cash | $37.85M |
| Net Cash Per Share | $0.71 |
| Working Capital | $34.46M |
| Shareholder Equity | $34.11M |
| Book Value Per Share | $0.64 |
| Total Assets | $38.81M |
| Total Liabilities | $3.97M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$12.72M |
|---|---|
| FCF Per Share | -$1.01 |
| Depreciation and Amortization | $22.51K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -457872.76%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -457872.76% |
| Pretax Margin | -423878.66% |
| Net Margin | -423878.66% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -40.28% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -40.28% |
Dividends and Yields
APRE does not pay a dividend.
| Buyback Yield | -150.18% |
|---|---|
| Shareholder Yield | -150.18% |
Stock Splits
The last split was a 1-for-20 reverse split on Feb 13, 2023.
| Last Split Date | Feb 13, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About APRE
What is APRE's market cap?
Aprea Therapeutics has a market cap of $5.91M.
How many shares of APRE are outstanding?
Aprea Therapeutics has 53.68M shares outstanding. The count is up 742.33% from a year earlier.
Does APRE pay a dividend?
No. Aprea Therapeutics does not pay a dividend.
How much debt does APRE have?
Aprea Therapeutics has $0 of total debt and $37.85M of cash and equivalents, a net cash position of $37.85M.
APRE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors